INTRODUCTION

Cancer is a disease that has been increasing its incidence in developed and developing countries, expecting an increase of cases of 47% (28.4 million) between 2020-2040, due to risk factors other than only socioeconomic or modifiable factors such as overpopulation but also non-modifiable factors such as age^1-4.

This global expansion, positions cancer as the leading cause of premature death, achieving a decrease of up to 3 years in life expectancy in countries such as Norway and Western Europe⁵. The Global Cancer Statics 2020, reported the occurrence of 19.3 million new cases of cancer and nearly 10 million deaths due to the same; it was also checked that breast cancer cases surpassed lung cancer with 2.3 million new cases (11.7%) against 11.4% respectively, although lung cancer remains the neoplasm with the highest mortality with 1.8 million deaths followed by colorectal, liver, stomach and breast cancer⁴.

Global studies in breast cancer have demonstrated that with standardization of age to 45.9 mortality and disability-adjusted life years (AVAD) have increased; also by means of the sociodemographic index (SDI) it was found that mortality decreased in females between the age ranges of 15-49 and 50-69⁶. Likewise, its incidence decreased in regions with high SDI and increased considerably in areas with medium and low SDI⁷.

Early detection of breast cancer in women plays a fundamental role, as a late diagnosis would favor progression of the neoplasm to advanced stages such as III or IV⁸. The causative factors of the delay in diagnosis are education, marital status, not recognizing the signs or symptoms of the disease, the fear of death, and not having health services nearby^9-11.

In several countries the possibility of employing medicinal plants as a complement or alternative treatment has opened up low cost and easily accessible in certain regions, being Peru a megadiverse country in terms of plant species some researchers recognize their therapeutic contributions as it is a case of Morinda citrifolia, Annona muricata, Uncaria tomentosa, Cenchrus echinatus L, demonstrating anticancer properties^12-15.

It has been found that the ethanolic extract of Cenchrus echinatus L. possesses tannins, phenolic compounds, alkaloids, flavonoids, and free amino acids in higher proportion, and in lesser amounts of quinones and glycosides^13-15. Associating polyphenols as responsible for antiulcer, cardioprotective, hepatoprotective¹⁴, hypolipidemic¹⁵, anticancer^16-18and antioxidant^19-20.

In 2000 the OECD (Organization for Economic Cooperation and Development) recommended as necessary the determination of acute toxicity and mean lethal dose (DL50) of medicinal products^21-22. Possible spontaneous changes in rodent behavior are thus also evaluated²³. Being a harmless product when DL50 values exceed 5 000 mg/Kg^23-25.

There are wild species with mutagenic, estrogenic, and immunosuppressive properties among which we found DMBA and N-Methyl-N-nitrosourea (NMU)^26-28. Whereas DMBA induces the appearance of an average of 4.7 hormone-dependent mammary tumors in mice, with histopathologic features and genetic alterations of the neoplasia described in humans²⁹.

At present, there are a limited number of plant products studied, their components, the determination of their therapeutic effectiveness, and the dosage to use. For such reasons we set out to determine the safety and protective effect of the ethanolic extract of Cenchrus echinatus L. (cadillo) on DMBA-induced breast cancer in Rattus rattus.

METHODS

RESULTS

InTable 1, it can be appreciated that the ethanolic extract of Cenchrus echinatus contains tannins, phenolic compounds, alkaloids, flavonoids, and free amino acids in abundant amounts, quinones, and glycosides in regular amounts, without identifying the presence of triterpenic steroids.

InFigure 1, the number of deaths of mice due to oral administration of increasing concentrations of ethanolic extract of Cenchrus echinatus L. from 10 mg/Kg up to 20 000 mg/Kg of weight, is observed being the DL50 (dose causing death of 50% of the specimens) of 16 223 mg/Kg.

Figure 1:  Oral safety at single dose DL50, of the ethanolic extract of Cenchrus echinatus L 

InTable 2, a. Blood biochemistry values evaluated during the oral safety assessment at 45 days of the ethanolic extract of Cenchrus echinatus L., represented by: Total cholesterol, High-density lipoprotein (HDL), triglyceride, glucose, urea, Pyruvic Glutamic Transaminase, are shown (TGP), alkaline phosphatase. Also in b. Leukocyte numbering and formula values are evidenced represented by the amount of: Stocked, segmented, eosinophils, basophils, monocytes, lymphocytes and leukocytes. Similarly in c. It shows the weights of rat soft organs such as stomach, spleen, kidney, liver, lung, heart and brain. All parameters are shown considering the measured value with their respective standard error, the treatment groups were conformed by male (M) and female (H) rats, which received SSF 5 mL/Kg and 100 mg/kg of Cenchrusechinatus L respectively.

InTable 3, The parameters considered when evaluating the protective effect of the ethanolic extract of Cenchrus echinatus L. at week 16 of experimentation are shown as follows: 3a. blood biochemistry represented by: Total cholesterol, High-density lipoprotein (HDL), triglyceride, glucose, urea, Pyruvic Glutamic Transaminase (PGT), alkaline phosphatase. Also in 3b. Leukocyte numbering and formula values represented by: Stored, segmented, eosinophils, basophils, monocytes, lymphocytes and leukocytes are evident. All parameters are shown considering the measured value with their respective standard error, the treatment groups were conformed by female rats.

InFigure 2, 2a. a higher amount of tumor mass formation is appreciated in the DMBA 20 mg/mouse group (39 units), distributed 23 at the thoracic level, six at the abdominal level and ten at the inguinal level, as well as a lower tumor mass formation in the group who received DMBA + Cadillo 200 mg/Kg with a total of nine tumor masses distributed seven at the thoracic level and two at the inguinal level. It is also observed in 2b. In relation to the group that received the DMBA 20 mg/mouse (39 tumor masses) and the DMBA + goat 200 mg/kg group (nine tumor masses) there is a 76.92% percentage inhibition of tumor masses.

Figure 2: Evaluation of the protective effect of ethanolic extract of Cenchrus echinatus L. a. Number and location of tumor masses. b. Number of tumors per treatment and inhibition percentage of tumor masses 

Figure 3:  Anatomopathological study of tumor masses when evaluating the protective effect of Cenchrus echinatus L on DMBA-induced breast cancer in mice (target 400X) 

InFigure 3. The anatomopathological study of the tumor masses is observed: 3a. Normal mammary gland; 3b and 3c. Hyperplastic zones and mammary adenocarcinoma. 3d. Breast adenocarcinoma with metastasis. 3e. Mammary gland with inflammatory infiltration. 3f. Mammary gland with lymph node plus infiltration of mononuclear cells in muscle zone.

DISCUSSION

Cenchrus echinatus L. is an annual plant, native to America, of the family Poaceae, of caespitose nature with erect or decumbent, branched and glabrous stems 15-85 cm high, can be found on beaches, disturbed sites, tropics and subtropics; at an altitude of 0-760 meters⁴⁰.

The phytochemical study of the extract evidenced the presence of abundant amount of flavonoids, which besides presenting low toxicity is considered a safe use plant product, with protective activity on breast cancer, as well as antioxidant, anti-inflammatory properties, among others⁴¹.

When evaluating the oral toxicity of the ethanolic extract of Cenchrus echinatus L., it was observed, a median lethal dose (DL50) of 16 223 mg/kg, besides a sustained increase in weights of the mice from 27 - 33 g for 14 days, failing to evidence signs of toxicity or death of mice at doses above 5000 mg/kg orally, considered virtually nontoxic⁴². In addition, according to European Community standards (2000) it classifies acute oral toxicity, as non-toxic when the dose of 2000 mg/kg is exceeded. Being able to compare this with OECD Guideline 407 where in one study two well-known immunosuppressants, azathioprine (AZA) and cyclosporine A (CysA), were chosen as model compounds in a dose range that did not cause visible toxic signs in animals during a treatment period of 28 days⁴³.

In the evaluation of oral safety at 45 days it was found that Cenchrus echinatus L. extract did not interfere with the development of albino rats as the body weights of the specimens increased in a gradual manner in all groups from 78-170 g; the blood biochemistry values (Total cholesterol, HDL, glucose, urea, TGP, alkaline phosphatase, supplied, segmented, eosinophils, basophils, monocytes, lymphocytes and leukocytes) and the macroscopic study of the soft organs (Stomach, spleen, kidney, liver, lung, heart and brain) showed no important alterations, the variations found are within the range established in the CENPALAB, 2010 for this species^44-45.

DMBA is an aromatic, highly lipophilic polycyclic hydrocarbon, which, to cause breast carcinogenicity requires its bioactivation and interaction with DNA, becoming epoxides and generating increased free radical formation, where lobes one and two of the gland mammary present the highest cell proliferative index and hence have more metabolic activity, which remains confirmed with our results since we observed a higher proliferation of tumor masses in the group receiving only DMBA (4 tumors per mouse), locating the highest proliferation at thoracic level.

On the other hand, estrogens are known to be responsible for breast cancer initiation and promotion; thus, inhibition of estrogen synthesis by lutein (4-tetrahydrochalcone) may be effective in breast cancer prevention by strongly inhibiting aromatase. Adding that possibly, some substances present in the Cenchrus echinatus L. extract may have favored the findings obtained in the present study.

Our main finding was the protective efficacy of the ethanolic extract of Cenchrus echinatus L., when a decrease in the appearance of tumor masses was evidenced from 39 units with DMBA to nine units with Cenchrus echinatus L 200 mg/Kg. Being compared with a study conducted in 32 21-day-old female Sprague Dawley rats, to which N-methyl-N-nitroso urea (NMU) was administered intraperitoneally, they found that sirolimus treatment decreased the expressions of ER and PgR of breast cancer already in turn reduced the size of tumor masses⁴⁶.

In a study where NMU was employed as a breast cancer inducer and sirolimus as treatment, the histology of the tumor masses presented no histologic subtypes of aggressive invasive carcinoma of no special type (NST)⁴⁶, whereas in our study one was evidenced epithelial and myoepithelial proliferation of the cells in most of the breast tumors, showed an anticancer efficacy of the extract of 30.76%, 64.10% and 76.92% at doses of 10, 100 and 200 mg/Kg of caddy extract respectively, whose protective effect is attributed to the presence of flavonoids that induce apoptosis by activating caspase 8 and Bax, inhibiting Bcl-2 expression and allowing cytochrome C release⁴⁷.

Therefore, breast cancer being a major health problem globally, with higher frequency in women, the search for new safe and effective products to tackle this disease becomes necessary²⁹.

The results of this research work presented its limitations in terms of observing the behavior of experimental animals during the assessment of the oral safety of the extract, as well as conducting long-term safety studies such as chronic toxicity, with the administration of treatments by other routes of administration and the incorporation of parameters such as reactive oxygen species in blood, as well as antioxidant and antiangiogenic activity of the extract could support the present study.

CONCLUSION

The ethanolic extract of Cenchrus echinatus L was obtained, which considering important secondary metabolites such as flavonoids, phenolic compounds and tannins in higher amount is considered as safe use plant product and besides would have implications on breast cancer.

Under experimental conditions it has been shown that the ethanolic extract of Cenchrus echinatus L. administered orally for 16 weeks is protective against 7,12-Dimethylbenzo[a]anthracene-induced breast cancer in female rats, upon evidence of a decrease in the number of y size of the tumor masses, as well as a greater protection from the ethanolic extract of Cenchrus echinatus L. at a dose of 200 mg/Kg.